AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1. (Currently amended) An isolated polypeptide consisting of ~~comprising~~ an unbroken sequence of amino acids from SEQ ID NO:1 that complexes with a major histocompatibility complex molecule type HLA-A2, wherein the amino acid sequence of said isolated polypeptide is not that set out in either of SEQ ID NOs:1 and 2, or that coded for by nucleotides 334-918 of SEQ ID NO:7, or GLEGAQAPL (SEQ ID NO:50), or FLLFKYQMK (SEQ ID NO:48), or FIEGYCTPE (SEQ ID NO:49).

2. (Currently amended) An isolated polypeptide consisting of ~~comprising~~ an unbroken sequence of amino acids from SEQ ID NO:1, that elicits an immune response from human lymphocytes, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ ID NOs:1 and 2, or that coded for by nucleotides 334-918 of SEQ ID NO:7, or GLEGAQAPL (SEQ ID NO:50).

3. (Canceled)

4. (Currently amended) A nonapeptide consisting of ~~comprising~~ an unbroken sequence of amino acids from SEQ ID NO:1, wherein the amino acid adjacent to the N-terminal amino acid is L or M, and the C-terminal amino acid is L, V, or I, other than a nonapeptide having the sequence CLGLSYDGL (SEQ ID NO:57), or GLEGAQAPL (SEQ ID NO:50).

5. (Previously presented) A nonapeptide as claimed in claim 4, wherein the amino acid in position 3 is Y and/or the amino acid in position 4 is D and/or the amino acid in position 5 is G and/or the amino acid in position 7 is E and/or the amino acid in position 8 is H.

6.-8. (Canceled)

9. (Currently amended) A nonapeptide having the amino acid sequence GLYDGMEHL (SEQ ID NO:42) ~~or GLYDGREHS (SEQ ID NO:43)~~.

10. (Withdrawn) A decapeptide having the amino acid sequence GLYDGMEHLI (SEQ ID NO:44) or GLYDGREHSV (SEQ ID NO:45).

11.-41. (Canceled)

42. (Previously presented) The nonapeptide of claim 4, wherein the amino acid adjacent to the N-terminal amino acid is L.

43. (Previously presented) The nonapeptide of claim 4, wherein the C-terminal amino acid is L.

44. (Previously presented) The isolated polypeptide of claim 1, the polypeptide being a nonapeptide wherein the amino acid adjacent to the N-terminal amino acid is L or M, and the C-terminal amino acid is L, V, or I.

45. (Previously presented) The isolated polypeptide of claim 44, wherein the amino acid adjacent to the N-terminal amino acid is L.

46. (Previously presented) The isolated polypeptide of claim 44, wherein the C-terminal amino acid is L.

47. (Previously presented) The isolated polypeptide of claim 2, the polypeptide being a nonapeptide wherein the amino acid adjacent to the N-terminal amino acid is L or M, and the C-terminal amino acid is L, V, or I.

48. (Previously presented) The isolated polypeptide of claim 47, wherein the amino acid adjacent to the N-terminal amino acid is L.

49. (Previously presented) The isolated polypeptide of claim 47, wherein the C-terminal amino acid is L.

50. (Canceled)

51. (Withdrawn) A decapeptide comprising the nonapeptide of claim 44.

52. (Previously presented) The isolated polypeptide of claim 1, wherein the polypeptide elicits an immune response from human lymphocytes.

53. (Previously presented) The isolated polypeptide of claim 52, wherein the polypeptide elicits an immune response from human lymphocytes when complexed with a major histocompatibility complex molecule type HLA-A2.

54. (Previously presented) The isolated polypeptide of claim 52, wherein the immune response is a cytolytic response from human T-lymphocytes.

55. (Previously presented) The isolated polypeptide of claim 1, wherein the major histocompatibility complex molecule type HLA-A2 is HLA-A2.1.

56. (New) A nonapeptide having the amino acid sequence GLYDGREHS (SEQ ID NO:43).